Cytokinetics Inc (NASDAQ:CYTK) has a beta value of 0.72 and has seen 0.47 million shares traded in the recent trading session. The company, currently valued at $3.85B, closed the recent trade at $32.26 per share which meant it gained $0.57 on the day or 1.80% during that session. The CYTK stock price is -100.28% off its 52-week high price of $64.61 and 1.83% above the 52-week low of $31.67.
The consensus among analysts is that Cytokinetics Inc (CYTK) is Buy stock at the moment, with a recommendation rating of 1.36. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 12 have rated it as a Hold, with 11 advising it as a Buy. 0 have rated the stock as Underweight.
Cytokinetics Inc (NASDAQ:CYTK) trade information
Sporting 1.80% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CYTK stock price touched $32.26 or saw a rise of 11.1%. Year-to-date, Cytokinetics Inc shares have moved -31.41%, while the 5-day performance has seen it change -12.01%. Over the past 30 days, the shares of Cytokinetics Inc (NASDAQ:CYTK) have changed -14.76%.
Wall Street analysts have a consensus price target for the stock at $61, which means that the shares’ value could jump 47.11% from the levels at last check today.. The projected low price target is $55.0 while the price target rests at a high of $67.0. In that case, then, we find that the latest price level in today’s session is -107.69% off the targeted high while a plunge would see the stock gain -70.49% from the levels at last check today..
Cytokinetics Inc (CYTK) estimates and forecasts
The company’s shares have lost -41.86% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -20.02% over the past 5 years. Earnings growth for 2025 is a modest -8.77% while over the next 5 years, the company’s earnings are expected to increase by 15.71%.
CYTK Dividends
Cytokinetics Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cytokinetics Inc (NASDAQ:CYTK)’s Major holders
The top two institutional holders are BLACKROCK INC. with over 14.67 million shares worth more than $794.97 million. As of 2024-06-30, BLACKROCK INC. held 13.4317% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 11.52 million shares as of 2024-06-30. The firm’s total holdings are worth over $624.32 million and represent 10.5485% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and iShares Trust-iShares Core S&P Mid-Cap ETF . As of Jan 31, 2025 , the former fund manager holds about 3.41% shares in the company for having 4.07 shares of worth $130.3 million while later fund manager owns 3.85 shares of worth $123.47 million as of Mar 31, 2025 , which makes it owner of about 3.23% of company’s outstanding stock.
